CORAUTUS ANNOUNCES UPDATE ON GENASIS TRIAL

Corautus Genetics has given an update on its GENASIS Phase IIb clinical trial, which is evaluating the safety and efficacy of VEGF-2 for the treatment of severe angina resulting from cardiovascular disease.

The company expects to complete the enrollment of 404 patients in the GENASIS trial in June 2006. The company has received a blinded interim variability analysis of the GENASIS trial data for the first 171 patients treated in the trial. The trial size was determined based on earlier Phase IIa results, to support a statistically significant determination of the effect of treatment in achieving the study endpoint.